OPTN · OptiNose

-

Please sign in to comment on OPTN

1 Comment

Admin

4 years ago

OptiNose, Inc is currently in a long term downtrend where the price is trading 24.0% below its 200 day moving average.

From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.5.

OptiNose, Inc's total revenue rose by 47.5% to $16M since the same quarter in the previous year.

Its net income has increased by 4.5% to $-24M since the same quarter in the previous year.

Finally, its free cash flow fell by 5.9% to $-19M since the same quarter in the previous year.

Based on the above factors, OptiNose, Inc gets an overall score of 3/5.

Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
Exchange	NASDAQ
CurrencyCode	USD
ISIN	US68404V1008

Beta	-0.88
Market Cap	94M
PE Ratio	None
Target Price	18
Dividend Yield	None

ABOUT

OptiNose

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase III clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. OptiNose, Inc.was founded in 2000 and is headquartered in Yardley, Pennsylvania.

OPTN · OptiNose

-

OptiNose

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest OptiNose using a moving average strategy